Nasdaq:US$18.41 (+0.16) | HKEX:HK$30.25 (+0.95) | AIM:£2.96 (+0)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2014-06-03

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer